Mathias Vormehr

Mainz, RP, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 36 publications

Messenger RNA delivery of a dual CD25/CD122 affinity-tuned IL-2 variant prolongs exposure and potentiates antitumor T cell immunity.

Messenger RNA delivery of a dual CD25/CD122 affinity-tuned IL-2 variant prolongs exposure and potentiates antitumor T cell immunity.

Journal: Science advances
Published: September 04, 2026

Author Correction: BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans.

Author Correction: BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans.

Journal: Nature
Published: July 16, 2025

Long-lasting mRNA-encoded interleukin-2 restores CD8+ T cell neoantigen immunity in MHC class I-deficient cancers.

Long-lasting mRNA-encoded interleukin-2 restores CD8+ T cell neoantigen immunity in MHC class I-deficient cancers.

Journal: Cancer cell
Published: August 13, 2024

Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial.

Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial.

Journal: Nature medicine
Published: January 08, 2024

RNA-encoded Interleukin 2 with Extended Bioavailability Amplifies RNA Vaccine-Induced Antitumor T-cell Immunity.

RNA-encoded Interleukin 2 with Extended Bioavailability Amplifies RNA Vaccine-Induced Antitumor T-cell Immunity.

Journal: Cancer immunology research
Published: September 19, 2023

Long-lasting mRNA-encoded interleukin-2 restores CD8+ T cell neoantigen immunity in MHC class I-deficient cancers.

Long-lasting mRNA-encoded interleukin-2 restores CD8+ T cell neoantigen immunity in MHC class I-deficient cancers.

Journal: Cancer cell
Published: July 25, 2023

MC38 colorectal tumor cell lines from two different sources display substantial differences in transcriptome, mutanome and neoantigen expression.

MC38 colorectal tumor cell lines from two different sources display substantial differences in transcriptome, mutanome and neoantigen expression.

Journal: Frontiers in immunology
Published: November 18, 2022

An Fc-inert PD-L1×4-1BB bispecific antibody mediates potent anti-tumor immunity in mice by combining checkpoint inhibition and conditional 4-1BB co-stimulation.

An Fc-inert PD-L1×4-1BB bispecific antibody mediates potent anti-tumor immunity in mice by combining checkpoint inhibition and conditional 4-1BB co-stimulation.

Journal: Oncoimmunology
Published: February 21, 2022

Publisher Correction: COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses.

Publisher Correction: COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses.

Journal: Nature
Published: January 20, 2021

mRNA therapeutics in cancer immunotherapy.

mRNA therapeutics in cancer immunotherapy.

Journal: Molecular cancer
Published: January 18, 2021

BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans.

BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans.

Journal: Nature
Published: December 09, 2020

Dexamethasone premedication suppresses vaccine-induced immune responses against cancer.

Dexamethasone premedication suppresses vaccine-induced immune responses against cancer.

Journal: Oncoimmunology
Published: September 14, 2020
Showing 1-12 of 36

Last Updated: 09/26/2026